VISTAGEN THERAP. DL-,001 Forum: Community User: DenManTau4

https://kalkinemedia.com/us/amp/business-news/pharma/brief-vistagen-therapeutics-on-march-7-received-letter-from-nasdaq-that-co-granted-until-sept-5-2023-to-regain-compliance-with-min-bid-price-requirement

https://seekingalpha.com/news/3943768-vistagen-readies-12m-share-secondary-offering VistaGen readies 12M-share secondary offering • VistaGen (NASDAQ:VTGN) down 4.3% premarket after filing a prospectus to sell 12.4M common shares by selling stockholders. • The company will not receive any proceeds from the sale of the shares offered. • This prospectus does not necessarily mean that the selling stockholders will offer or sell those shares. • Recently, VTGN secured new U.S. patent for PH80 nasal spray for migraine.

VistaGen Therapeutics (VTGN) Announces 12.41M Share Offering ... https://www.streetinsider.com/dr/news.php?id=21318243

https://www.streetinsider.com/dr/news.php?id=21304145&gfv=1

Bissel Bewegung zum Feierabend 🍀

Nach der letzten Welle jetzt misstrauisch.... eigentlich jetzt Kursziel 1 Dollar....bis Juni, July....

....ziehhhhhhh

Keine 30%...bin ich ein wenig enttäuscht....ich will die 0,21 Dollar zurück

Gut das dreifache vom sonst üblichen Volumen 👍

Schöner Umsatz....auch....

So viel Stress vor dem Wochenende 😅

Dead Cat bounce?

Ich glaube, ich brauche was von Vistagen....grins...ganz schön anstrengend...jetzt wieder 20% hoch....

0,21 Dollar muss im Tageskerzen Chart als Unterstützung halten.

Eigentlich besser als erwartet... trotzdem erstmal rückwärts.

VistaGen Therapeutics Q3 EPS $(0.05) Beats $(0.07) Estimate, Sales $179.60K Beat $150.00K Estimate https://www.benzinga.com/news/earnings/23/02/30780414/vistagen-therapeutics-q3-eps-0-05-beats-0-07-estimate-sales-179-60k-beat-150-00k-estimate VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is unchanged from the same period last year. The company reported quarterly sales of $179.60 thousand which beat the analyst consensus estimate of $150.00 thousand by 19.73 percent. This is a 49.82 percent decrease over sales of $357.90 thousand the same period last year.